Overview
LTRN market data
Price History
No market bars yet for LTRN. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for LTRN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Lantern Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For 'Methods For The Treatment Of Solid Tumor Cancers Using Illudins And Biomarkers'Benzinga · Jul 23, 2026, 12:09 PM
Lantern Pharma Launches ZetaOmics, A Computational-Biology Module Of Its WithZeta.ai Co-Scientist PlatformBenzinga · Jul 8, 2026, 11:40 AM
Lantern Pharma Announces Selling Stockholders May Sell Up To 2.24M Shares Of Common StockBenzinga · Jun 12, 2026, 8:40 PM
Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLCBenzinga · Jun 2, 2026, 12:19 PM
8-K filing — Lantern Pharma Inc. (LTRN)SEC EDGAR · Jun 1, 2026, 11:40 PM
Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer AdenocarcinomaBenzinga · May 19, 2026, 11:40 AM
Lantern Pharma shares are trading lower. The company reported Q1 financial results.Benzinga · May 15, 2026, 9:03 PM
Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) EstimateBenzinga · May 15, 2026, 8:02 PM
Earnings Scheduled For May 15, 2026Benzinga · May 15, 2026, 11:15 AM
Lantern Pharma shares are trading higher after Lantern Pharma announced up to a $9.25 million direct offering with existing shareholders.Benzinga · May 13, 2026, 3:40 PM